Post by Boston Scientific on X
Boston Scientific@bostonsci
XWe’ve agreed to acquire @BoltIVL, developer of an intravascular lithotripsy (IVL) offering to treat coronary and peripheral disease, which will expand our cardiovascular portfolio with a complementary & differentiated calcium modification platform. t.co $BSX
29 likes0 repliesPosted Jan 8, 2025